通过回输调节性T细胞(Tregs)的过继免疫疗法是近年来个体化免疫治疗1型糖尿病(T1D)的研究热点，但目前的治疗方法仍存在不足，且缺少无创的活体检测手段来长期监测Tregs的命运和评估β细胞的状态。研究发现，胰岛素样生长因子-I(IGF-I)能够以自分泌/旁分泌的方式发挥免疫调控功能，刺激Tregs增殖、维持免疫抑制功能及促使其靶向移行。结合前期研究基础，我们拟利用杆状病毒-睡美人转座子新型载体介导IGF-I和钠碘同向转运体(NIS)在Tregs中长期高效表达，以实现IGF-I对Tregs的调控，增强其生物学特性，并利用NIS报告基因监测Tregs的移行、分布和数量；同时利用核素标记的lixisenatide进行β细胞的核素显像，以探索IGF-I自分泌/旁分泌协同Tregs过继治疗T1D的内在机制和评估其疗效，并通过与其他治疗方法的比较，为Tregs过继治疗T1D及其疗效监测提供新策略。

Adoptive immunotherapy by transfusion autologous regulatory T cells (Tregs) is the research highlights of type 1 diabetes (T1D) individualized immunotherapy in recent years. However, there are still several defects, as well as the absence of non-invasive detection methods for in vivo monitoring the fate of Tregs and assessing the state of beta cells for a long term. Recent studies found that insulin-like growth factor-I (IGF-I) can regulate the immune function to stimulate the proliferation of Tregs, to maintain the immune suppression effects of Tregs and to prompt their targeting migration in vivo by an autocrine/paracrine manner. Combining with early research work, we propose to use a novel baculovirus-sleeping beauty transposon vector system mediating high efficient and long-term expression of IGF-I and sodium iodine symporter (NIS) transgenes in Tregs, through which IGF-I will regulate the Tregs, enhancing their biology characteristics, and the migration, distribution and proliferation of Tregs will be monitored by NIS reporter gene imaging. At the same time, the radionuclide labelled lixisenatide will also be used to monitor the beta cells for exploring the intrinsic mechanism and assessing the therapeutic effect of synergetic therapy of T1D by Tregs adoptive immunotherapy combined with IGF-1 autocrine/paracrine. Furthermore, by comparing the therapeutic effect with other immunotherapy methods, we will provide novel and potential strategies for Tregs adoptive immunotherapy as well as their therapeutic effect monitoring in T1D.